<DOC>
	<DOC>NCT02828254</DOC>
	<brief_summary>The purpose of this study To evaluate the safety and efficacy of PRI-724 administration in patients with cirrhosis due to hepatitis C by 12-month follow-up.</brief_summary>
	<brief_title>A Follow-up Evaluation Study of PRI-724-1101</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1. Having been administered PRI724 in Study 1101 after being confirmed to meet the inclusion criteria and not to meet the exclusion criteria and consenting to participate in the study. 2. Having provided voluntary written consent for participation in this study. 1. Patients who are pregnant or may be pregnant, or who desire to become pregnant or may be pregnant during the clinical study [excluding patients who have undergone a sterilization procedure or postmenopausal patients (if amenorrhea without medical reasons continues more than 12 months), patients who are nursing. 2. Patients who do not consent to practice birth control during the clinical study (including male patients). 3. Patients with serious allergy to contrast media or a history thereof. 4. Patients with a history of drug or alcohol addiction within five years at the time of providing written consent or a history of drug or alcohol abuse within the past one year. 5. Patients contraindicated for liver biopsy. However, this criterion will not apply to a patient who has turned out to be contraindicated for liver biopsy after having been administered PRI724 in Study 1101. 6. Patients who participated in another clinical trial, except PRI7241101 trial, within 30 days at the time of providing written consent. 7. Patients who have discontinued administration of PRI724 in Study 1101 due to death or other reasons and become lost for followup. 8. Other, at the point when Study 1101 has been completed (or discontinued), patients who are judged inappropriate for inclusion in the study by the investigator for such reasons as the presence of serious pathological condition.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>